This program is supported by a educational grant from Amgen.
David C. Dale, MD has been Professor of Medicine in the Department of Medicine at the University of Washington in Seattle for more than 25 years. He received a medical degree from Harvard University, residency training at the Massachusetts General Hospital and the University of Washington and served as a senior investigator with the National Institute of Allergy and Infectious Diseases’ Laboratory of Clinical Investigation at the National Institutes of Health in Bethesda, Maryland. Other past positions include serving as dean of the School of Medicine at the University of Washington.
Dr. Dale is president-elect of the American College
of Physicians (ACP) for 2006-2007, editor-in-chief of ACP Medicine,
and an editorial board member of Clinical Advances in Hematology
and Oncology and Journal of Experimental Hematology. His research
interests center on neutrophil physiology, neutropenia, and hematopoietic
growth factors, and he has published widely on these subjects in
journals such as Supportive Cancer Therapy, Journal of Supportive
Oncology, Drugs, Seminars in Oncology, Journal of Clinical Oncology,
Blood and American Journal of Hematology. He has also written
chapters and sections for the Merck Manual, Williams Hematology,
Blood: Principles and Practice of Hematology, Clinical Hematology
and ACP Medicine 2006.
Dr. Dale currently serves on the National Board
of Sponsors for Physicians for Social Responsibility and is co-director
of the Severe Chronic Neutropenia International Registry.
Michael Rader, MD is a Clinical Assistant Professor of Medicine at the Columbia University College of Physicians and Surgeons. He is the director of the Union State Bank Cancer Center at Nyack Hospital. Dr. Rader graduated college from the City College of the City University of New York, Phi Beta Kappa, Magna Cum Laude. He attended medical school at the State University of New York, Downstate Medical Center. Dr. Rader completed his internship and residency at State University-King County Medical Center in Brooklyn New York. He completed his fellowship in Hematology at Montefiore Medical Center, Albert Einstein College of Medicine and his medical oncology training at Memorial Sloan Kettering Cancer Center.
Robert E. Smith, MD is the President of South Carolina
Oncology Associates PA, a 19 physician multi-specialty practice including
medical, radiation, and gynecologic oncology located in Columbia,
South Carolina. Dr. Smith also serves as the Director of the Cancer
Treatment and Research Institute at Baptist Medical Center and is
a Clinical Associate Professor at the University of South Carolina
School of Medicine, both in Columbia.
Dr. Smith is a magna cum laude graduate of
Erskine College in Due West, South Carolina. Dr. Smith earned his
Doctor of Medicine degree from the University of Virginia School
of Medicine in Charlottesville, Virginia. He completed an internship
and residency in internal medicine and a fellowship in medical oncology
at Dartmouth Hospitals in Hanover, New Hampshire.
Dr. Smith is board certified in internal medicine
and medical oncology. He is an associate of the American College
of Physicians and a diplomat of the American Board of Internal Medicine.
Dr. Smith just completed a term as President of the South Carolina
Oncology Society and is a member of the American Society of Clinical
Oncology where he serves on the Clinical Practice Committee, the
American Society of Hematology, ESMO, the South Carolina Medical
Association, and the Columbia Medical Society.
Dr. Smith is active in clinical research and
an invited lecturer in oncology. Dr. Smith has been published in
the American Society of Clinical Oncology Proceedings, Clinical
Research, Cancer, JCO, JAMA, British Journal of Cancer, and
European Journal of Cancer.
Christopher R. Friese, RN, PhD is currently research fellow at the Center for Outcomes and Policy Research and Associate Clinical Scientist at the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is also a fellow in Cancer Prevention and Control at the Harvard School of Public Health. Dr. Friese conducts research on outcomes of care for patients with cancer, and organizational factors associated with quality of care. He is principal investigator of the Oncology Nursing Society Foundation–funded study Neutropenia Outcomes: Nurse Staffing and Practice Environment Effects. He has received research funding from the National Institute of Nursing Research, the American Cancer Society, and the Oncology Nursing Society. He completed his bachelor, masters, and doctoral degrees at the University of Pennsylvania. He serves on the advisory board of the doctoral program in nursing, cancer, and health disparities at the University of Massachusetts-Boston.
Dr. Friese received a Young Investigator award from the Multinational Association ofSupportive Care in Cancer in 2005 and a Merit Award from the American Society of Clinical Oncology in 2006. He lectures nationally and internationally on the topic of supportive care in cancer. His research findings have been published in Nursing Research, Oncology Nursing Forum, and the Clinical Journal of Oncology Nursing. He is research consultant and co-author of the Oncology Nursing Society’s Putting Evidence Into Practice: Evidence Based Summary for the Prevention of Infection. He has practiced in some of the nation’s leading cancer centers, including the Kimmel Cancer Center at Johns Hopkins, the Abramson Cancer Center at the University of Pennsylvania, and the Fox Chase Cancer Center. Dr. Friese remains an active nurse clinician in the hematologic malignancies/bone marrow transplant setting.
Faculty Disclosure Declarations:
David C. Dale, MD – Research Support recipient, Consultant, Speakers’ Bureau – Amgen
Michael Rader, MD - Research Support recipient, Consultant, Speakers’ Bureau – Amgen
Robert E. Smith, MD - Research Support recipient, Advisor Panel member, Speakers’ Bureau – Amgen, Genentech
Christopher Friese, RN, PhD - Consultant, Speakers’ Bureau, Stockholder – Amgen
Stockholder – Novartis, Palatin Technologies
Disclosure Policy:
It is the policy of ArcMesa Educators to ensure balance, independence, objectivity, and scientific rigor in all CME activities. All faculty/authors are expected to disclose any relevant financial relationships they may have with commercial interests in relation to this activity. These relationships, along with the educational content of this program, have been reviewed and any potential conflicts of interest have been resolved to the satisfaction of ArcMesa Educators.
Printer settings may vary. Please use landscape layout option.
